BioVersys AG (SWX:BIOV)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
34.00
+0.20 (0.59%)
At close: Jul 31, 2025, 5:20 PM CET
0.59%
Market Cap198.00M
Revenue (ttm)1.21M
Net Income (ttm)-18.72M
Shares Out5.82M
EPS (ttm)-5.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume608
Average Volume1,508
Open33.50
Previous Close33.80
Day's Range33.50 - 34.00
52-Week Range33.10 - 37.00
Betan/a
RSI45.27
Earnings Daten/a

About Activision Blizzard

BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 27
Stock Exchange SIX Swiss Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.